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Objectives: Age-related changes in articular cartilage are likely to play a role in the etiology of osteoar-
thritis (OA). One of the major age-related changes in cartilage is the accumulation of advanced glycation
end products (AGEs). The present study evaluates whether pentosidine can predict radiographic pro-
gression and/or burden over 5 years follow-up in a cohort of early knee and/or hip OA.
Design: The 5 years follow-up data of 300 patients from cohort hip & cohort knee (CHECK) were used.
Radiographic progression and burden were assessed by X-rays of both knees and hips (Kellgren and
Lawrence (K&L) and Altman scores). Baseline pentosidine levels (and urinary CTXII as a comparator)
were measured by high-performance-liquid-chromatography (HPLC) and enzyme linked immunosorbent
assay (ELISA). Univariable and multivariable associations including baseline radiographic damage, age,
gender, body mass index (BMI) and kidney function were performed.
Results: Both pentosidine and urinary C-terminal telopeptide of type II collagen (uCTXII) correlated with
radiographic progression and burden. In general pentosidine did not have an added predictive value to
uCTXII for progression nor burden of the disease. The best prediction was obtained for burden of radio-
graphic damage (R2¼ 0.60e0.88), bus thiswas predominantly determinedbybaseline radiographic damage
(without this parameter R2 ¼ 0.07e0.17). Interestingly, pentosidine signiﬁcantly added to prediction of
osteophyte formation, whereas uCTXII signiﬁcantly added to prediction of JSN in multivariable analysis.
Conclusion: Pentosidine adds to prediction of radiographic progression and burden of osteophyte for-
mation and uCTXII to radiographic progression and burden of JSN, but overall skin pentosidine did not
perform better that uCTXII in predicting radiographic progression or burden. Burden of damage over 5
years is mainly determined by radiographic joint damage at baseline.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction Schiff bases, Amadori rearrangement, and Maillard reactions sub-The pathogenesis of osteoarthritis (OA) is unknown. Several risk
factors are described, age being clearly one of the main factors. A
major age-related change in articular cartilage is the modiﬁcation
of proteins by non-enzymatic-glycation (NEG). NEG is a common
posttranslational modiﬁcation of proteins caused by reducing
sugars. The spontaneous condensation of reducing sugars with free
amino groups in lysine or arginine residues on proteins leads via.P.J.G. Lafeber, Rheumatology
enter Utrecht, PO Box 85500,
1; Fax: 31-30-2523741.
afeber).
s Research Society International. Psequently into advanced glycation end products (AGEs)1. As such,
NEG can result in adducts to a protein, changing its properties2, but
also in the formation of cross-links between proteins, changing the
integrity of the cartilage matrix3.
AGEs are only removed from tissues when the proteins involved
are degraded and removed. Cartilage tissue has a low turnover of its
proteins resulting in abundant AGE accumulation3,4 over the years.
As such these AGEs may be the intermediate in age-related pre-
disposition to OA.
In vitro investigations show thatAGEs have anegative inﬂuenceon
mechanical3,5 and biochemical2,6 properties of the cartilage tissue
making itmoreprone tomechanical damage. Invivo effectofAGEshasublished by Elsevier Ltd. All rights reserved.
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transaction (ACLT) model artiﬁcial elevated AGE levels of the joint
cartilage leads to an increase in progression of OA compared to joints
without elevated AGE levels7. Uponminimal applied surgical damage
of the cartilage according to the canineGroovemodel8 in combination
with restricted joint loading, artiﬁcial increase of AGE levels shows a
tendency to more severe OA progression9.
To further understand the role of AGEs in speciﬁcally human OA,
ideallycartilage biopsieswouldbeused to assessAGE levels and relate
those to OA development and/or progression in longitudinal study
designs. The drawback of such an approach ise amongst otherse the
possibility of interferingwith the diseaseprocess (the cartilage biopsy
may induce and/or accelerate OA development). An alternative and
more feasible approachmight be the use of the AGE characteristics of
another,more accessible, connective tissuewith relative lowturnover,
such as skin, as a surrogate for theAGE characteristics of cartilage.AGE
accumulation with increasing age in skin collagen is linearly corre-
lated to accumulation in cartilage4,10. Cartilage pentosidine is about
ﬁve times higher compared to skin pentosidine10. When using skin
pentosidine as a surrogate marker for cartilage pentosidine in a cross
sectional studyonearly radiographicOA, skinpentosidine is increased
inpatientswithmildOA compared to thosewithout OA10. Urine CTXII
is fromall biomarkers reported on thus far, the one that best relates to
development and progression of OA11e13. Moreover, this biomarker
has alreadybeenproven applicable in clinical trials tomonitor disease
activity and to decide on treatment of rheumatoid arthritis14. As such
this biochemicalmarker is a relevant comparator in case of studies on
biochemical markers of joint damage.
Up till now plain radiographs are the gold standard for imaging
hip and knee joint damage. These radiographs can be scored in
different ways. The K&L classiﬁcation15 is probably the most used
one. This method uses joint space narrowing (JSN), osteophyte
formation, and subchondral sclerosis in a combined score, whereas
the Altman atlas score16, scores these features independently. Both
these methods use a stepwise scoring (ordinal variable) (e.g., 0e4
for K&L and max 0e3 for JSN for Altman).
In a cross sectional study we showed in a cohort of patients with
very early signs of knee and/or hip OA (CHECK) that skin pentosi-
dinewas higher in participants withmore severe radiographic joint
damage as calculated by the sum of the K&L score of both hips and
knees10. The present study describes whether these skin pentosi-
dine levels are useful to predict progression of OA over 5 years
follow-up, compared to/or in addition to uCTXII, also taking de-
mographic and radiographic baseline characteristics into account.
Methods
Cohort description
Three-hundred participants from the Dutch CHECK cohort
(‘cohort hip & cohort knee’) were asked to participate. Participants
were included with pain and/or stiffness in hip and/or knee, aged
45e66 years, and never or no longer than 6 months had visited the
general practitioner for these complaints. Participants with a
known rheumatic condition, and Kellgren and Lawrence grade IV of
hip and/or knee were excluded. For details see Wesseling et al.17
This study was approved by medical ethical committee of the Uni-
versity Medical Centre (UMC) Utrecht and according to the decla-
ration of Helsinki. All participants gave written informed consent.
Skin pentosidine as surrogate markers of cartilage AGE
At baseline a full-thicknesspunch skinbiopsy (4mmØ)was taken
from the lower back according to standard procedures10. Pentosidine
was used as ameasure of the various AGEs formed. It is reported thatpentosidine represents a number of AGE markers such as Nε-(car-
boxymethyl)lysine andNε-(carboxyethyl)lysine18. Pentosidine in the
skin was measured by high-performance-liquid-chromatography
(HPLC) as described previously and the pentosidine content of
collagen samples is expressed as mmol/pmol collagen19.
Cartilage breakdown marker; uCTXII
uCTXII as a biomarker supposed for degradation of hyaline
cartilage type II collagen but supposedly also involved in bone
turnover20, was measured by ELISA (CartiLaps, Nordic Bioscience,
Denmark) according to manufacturer’s guidelines. Intra-assay and
inter-assay variation of the same sample were both 10%. Urinary
uCTXII values were normalized by urinary creatinine (Johnson &
Johnson Vitos 250 Clinical Chemistry Slides) to account for urinary
dilution. uCTXII is expressed as ngram/mmol creatinine.
Kidney function
As a potential confounder, kidney function was determined
since it might be related to skin pentosidine level and uCTXII due to
the fact that less excretion of plasma pentosidine and CTXII in
kidney dysfunction is seen21 and might also be related to more
severe disease. Creatinine in peripheral blood was measured by
Unicel DxC 800, Beckman Coulter (Fullerton, CA, USA). Estimated
glomerular ﬁltration rate was calculated by the CockrofteGault
formula22.
Radiographic joint damage
Radiographs of both knees and hips were taken from all par-
ticipants. Radiographs of tibio-femoral (TF) joints were made by a
weight-bearing posterior anterior view, and semi-ﬂexed (7e10)
according to Buckland-Wright16,23,17. For the hip, weight-bearing
anterior posterior radiographs of the pelvis were made24.
Radiographs of both knees and hips were obtained at baseline
(T0) and after 2 and 5 years (T2 and T5). All radiographs were
scored according to K&L15 with all three time points in view at the
same time, and known sequence.
Radiographic OA burden was expressed as the summed K&L
grade of both hips and knees. When a prosthesis was implanted (in
12 cases) the scoreþ 1 (unless alreadymaximum) of the latest time
point was used. Total scores were calculated by taking the sum of
the individual scores of the four joints leading to a maximum score
of 16. Also the different radiographic features were scored by using
the Altman atlas16. The Altman score provides scores of the joint
space narrowing (JSN; 0e3) at two places for the knees and two for
the hips. The sum of these scores was used to measure the overall
JSN of four joints (max. 24). The osteophyte formation is scored on
four different places in the knee as well as the hip (0e3 except for
acetabulum inferior 0e1). The sum of these scores was calculated
for a total score of the osteophyte formation of a patient (max 44).
Radiographic OA progression was expressed as the area under
the curve (AUC) of the summed K&L grade over the 5 years minus
the baseline value over 5 years. The burden of radiographic joint
damage was expressed as the AUC over 5 years. For the summed
Altman scores for JSN and osteophyte formation the same ap-
proaches were used to determine progression and burden scores per
patient.
Statistical analysis
Continuous variables were described using means with stan-
dard deviation (SD) or medians with twenty-ﬁfth and seventy-ﬁfth
Table IB
The radiographic characteristics at baseline and 5 years follow-up
T0 T5 P value
Mean  SD Minemax Mean  SD Minemax T0eT5
Sum K&L score 1.69  1.13 0e4 3.30  1.81 0e7 P < 0.001
Sum Altman JSN 3.40  2.58 0e11 4.97  3.02 0e14 P < 0.001
Sum Altman
osteophyte
3.34  3.01 0e15 6.47  4.52 0e22 P < 0.001
Sum K&L score calculated by taking the sum of the individual scores of the four
joints leading to a maximum score of 16. Sum Altman JSN and osteophyte scores are
the sum of the scores of the different locations (2 and 4, respectively) in all four
individual joints (max. 24 and 44, respectively). P values for Wilcoxon rank test are
given.
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using frequencies and percentages.
Skin pentosidine and uCTXII were divided in three equal groups
(tertiles) and the radiographic progression and burden scores were
compared between the group with the highest and the lowest
biomarker level and tested using ManneWhitney U tests.
Correlations of skin pentosidine levels as well as uCTXII levels
with radiographic progression and burden scores were investigated
by Pearson correlation.
Multivariable linear regression analyses were used to correct for
possible confounders and investigate the additional predictive
value of skin pentosidine/uCTXII above other predictors. In these
analyses age, gender, creatinine clearance, and body mass index
(BMI) as well as baseline radiographic scores were evaluated as
covariables. These variables were used based on known con-
founders from the baseline analysis. Final models were deﬁned
using a backward selection strategy starting removing variables
that were not statistically signiﬁcantly (based on a change in the
regression coefﬁcient of >10%). Since we carefully decided on var-
iables to include and outcomes to study and the plausibility of our
results we decided not to adjust our P values for that and use the
regular P value of 0.05.
A P value  0.05 was taken as statistically signiﬁcant and all
statistical analyses were performed using SPSS version 15.0.
Results
Characteristics of study population
The characteristics of the study population and of the radio-
graphic progression are shown in Tables IA and IB, respectively.
Sixty-ﬁve of the 300 participants did not contribute. In 61 cases
radiographic data were not complete for all three time points and/
or biochemical data were missing, so for 183 participants all data
were available and these were used in the current analyses. In total
nine participants reported to have diabetes. The baseline de-
mographics (age, gender, BMI, and kidney function) and baseline
radiographic characteristics did not differ statistically signiﬁcant
from the original 244 cohort patients. For all radiographic param-
eters statistically signiﬁcant progression of OA was seen (Table IB).
Differences in radiographic progression and burden between low
and high skin pentosidine as well as low and high uCTXII
To test whether patients with high vs low skin pentosidine/
uCTXII levels at baseline had a different progression and/or total
burden of radiographic OA over 5 years, the lowest and highest
tertiles of skin pentosidine/uCTXII were compared for radiographic
progression and burden scores (Fig. 1).
For skin pentosidine the AUC progression and burden sum K&L
score showed no difference between patients with the highest and
lowest tertile [Fig. 1(A)]. The same was found for AUC progressionTable IA
The baseline characteristics of the study population
Variable
Age (years)* 55.5  5.4 45e66
BMI (kg/m2)y 26.37 23.9e29.3
Gender (M/F)z 30/153
Skin pentosidine/collagen (mmol/mol)y 2.34 1.88e2.83
uCTXII (ngram/mmol)y 0.29 0.20e0.40
Creatinine clearance (ml/min/1.73 m2)* 93.8  22.1 52e170
* Mean values  SD with min and max values.
y Median values with 25e75 percentiles.
z Actual numbers of patients.and burden Altman JSN [Fig. 1(B)]. For Altman osteophytes the AUC
progression and burdenwere signiﬁcantly higher in the groupwith
high skin pentosidine [Fig. 1(C); P ¼ 0.001 and 0.024, respectively].
For the highest and lowest uCTXII tertiles, AUC progression and
burden scores [Fig. 1(DeF)] were all (except for one) statistically
signiﬁcant different, with the most severe damage scores for the
highest uCTXII level. When the participants with low skin pento-
sidine and low uCTXII were compared with those for both param-
eters in the highest tertile (n ¼ 21 and 17 for both lowest and both
highest combined tertiles, respectively) all radiographic charac-
teristics were more severe in the group with high compared to low
combined pentosidine and uCTXII values [Fig. 1(GeI)] and differ-
ences became clearly more outspoken, suggesting additive pre-
dictive ability.Correlation of skin pentosidine and uCTXII with radiographic
damage
In Table II correlations of skin pentosidine and uCTXII with
radiographic progression and burden for the overall (K&L) and
separate characteristics (JSN and osteophytes) are given. In general,
correlations with radiographic progression and burden were
stronger for uCTXII than for skin pentosidine. For uCTXII relations
with radiographic burden were in general stronger than for
radiographic progression. For skin pentosidine this was the other
way around.
Figure 2 provides representative ﬁgures for skin pentosidine
against sum K&L grade for progression and burden (A and B,
respectively) and for uCTXII for sumAltman JSN for progression and
burden (C and D, respectively).Multiple regression analysis
In Table III different ﬁnal regression models based on the
multivariable linear regression analysis are shown. Regression co-
efﬁcient and P values for the different independent variables in
each of the models are given. In case of the models for AUC burden
the R2 for each model with and without baseline radiographic
damage is given.
For the progression scores for all three radiographic outcome
parameters (sum K&L, Altman JSN, and Alman osteophytes) the
explained variance (R2) was low, between 0.03 and 0.23. For the
radiographic burden scores the R2 is higher, between 0.69 and 0.88.
Regarding burden, for all radiographic parameters, the baseline
radiographic parameter was most strongly related to outcome as
can be deduced from the high regression coefﬁcient (as compared
to the other variables in the models) and the signiﬁcant decrease in
explained variance when excluding these variables from the model
(i.e., for burden K&L from 0.69 to 0.14). For all three radiographic
parameters combining skin pentosidine with uCTXII in the models
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Fig. 1. Difference between progression and burden of radiographic OA for participants with low and high skin pentosidine, uCTXII or the combination. Participants with low (white)
and high (dashed) tertiles skin pentosidine (AeC; n ¼ 66 in the low and high group), urine CTXII (DeF; n ¼ 68 and 67 in the low and high group respectively), and both (GeI; n ¼ 21
and 17 in the low and high group, respectively) at baseline. Differences in sum K&L (A, D, G), sum Altman JSN (B, E, H), and sum Altman osteophytes (C, F, I) scores are given. Median
(dash), with the interquartile range (box; 50%) with the ﬁfth and ninety-ﬁfth percentiles (whiskers) are presented. P values are indicated.
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model, supporting the dominant role of the baseline radiographic
characteristics. In this analysis both skin pentosidine and uCTXII
were predictive of sum K&L score, progression and burden. Inter-
estingly, skin pentosidine did not (signiﬁcantly) add to prediction ofTable II
Correlations between skin pentosidine levels and uCTXII levels with radiographic
progression of OA and burden of OA
Skin pentosidine uCTXII
R P R P
Progression AUC
Sum K&L 0.167 0.024 0.323 <0.001
Sum Altman JSN 0.123 0.095 0.190 0.016
Sum Altman osteophytes 0.301 <0.001 0.194 0.014
Burden (total) AUC
Sum K&L 0.056 0.454 0.360 <0.001
Sum Altman JSN 0.113 0.127 0.332 <0.001
Sum Altman osteophytes 0.180 0.015 0.290 0.001
Statistical signiﬁcant P values are given in bold.sum Altman JSN, whereas uCTXII did, for progression and burden.
On the other hand skin pentosidine added to sum Altman osteo-
phyte score but uCTXII did not, again both for progression and
burden. In general BMI did not add to the model with uCTXII as
independent biomarker variable but did add to themodel with skin
pentosidine as biomarker independent variable.
Discussion
It was studied whether skin pentosidine better, alone or in
combination with uCTXII can predict radiographic progression and
burden of knee and hip joint damage very early in the osteoarthritic
disease process. In general skin pentosidine could not improve the
predictive ability of uCTXII for progression or burden of disease. The
best predictive models were obtained for burden of radiographic
damage, but this was predominantly determined by baseline
radiographic damage. Skin pentosidine signiﬁcantly added to pre-
diction of osteophyte formationwhereas uCTXII did not, and uCTXII
signiﬁcantly added to JSN whereas skin pentosidine did not.
A B
C D
Fig. 2. Correlations skin pentosidine and uCTXII with parameters of radiographic progression and burden. For skin pentosidine the sum K&L scores for progression and burden
(A and B, respectively) and for uCTXII the sum Altman JSN scores (C and D, respectively) are given as representative ﬁgures. Correlation coefﬁcients with P values for all relations are
given in Table II. Pearson correlation coefﬁcients with P values are provided.
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skin pentosidine is higher in participants with more severe radio-
graphic K&L hip and knee joint damage10. The present study dem-
onstrates that for progressionandburdenof disease over5 years this
association is lost. On the other hand, uCTXII at baseline was
discriminative for general (K&L) radiographic progression and
burden. Interestingly, when osteophyte formationwas evaluated as
an independent radiographic characteristic, skin pentosidine was
related to progression and burden over 5 years follow-up, whereas
this is not the case for JSN. But in regression analyses, despite sta-
tistical signiﬁcance, the explained variance was only marginally
increased and insufﬁciently to aid to prediction of radiographic
progression in individual patients. When the hips and knees were
analyzed separately, in univariable analysis the hip OA is more
associatedwith skinpentosidine and kneeOAmorewith urine CTXII
(Tables 2A and 2B, online). In multivariable analysis these minor
differences became less pronounced (Tables 3A and 3B, online).
When studying skin pentosidine or uCTXII a different aspect of
metabolism is studied. Skin pentosidine can be used to get more
insight in cartilage pentosidine levels4. The rate of collagen turn-
over in skin is around 14.8 years, and even longer in cartilage4,
resulting in accumulation of pentosidine over time into the tissue.
When using skin pentosidine in relation to radiographic damage
the effect of AGEing on OA during lifetime is investigated. uCTXII
level is a marker for cartilage degeneration11, at a certain point in
time and no cumulative measure as tissue pentosidine levels are.
CTXII is mostly detected in areas with collagen type II damage, but
also close to the bone suggesting that CTXII can be associated with
subchondral bone changes20,25. Moreover, pentosidine is studied tobe causative in joint degeneration, whereas uCTXII is the result of
joint degeneration. Irrespectively, skin pentosidine was compared
to uCTXII as uCTXII is at present suggested to be the best predictor
of radiographic joint damage in OA11,12. In case skin pentosidine
would be of use as a predictor, its predictive ability should out reach
that of uCTXII. This is of even more importance regarding the
invasiveness of taking skin biopsies followed by complex HPLC
analysis in comparison to analyzing a urine sample by ELISA. This
means that in clinical practice uCTXII is much easier to use. In case
skin pentosidine would have been a good predictor, alternative and
less invasive measurement for skin pentosidine such as skin auto
ﬂuorescence measurement26 could have been enhanced and
studied.
Despite the difference in both markers and the difference in
their predictive ability, osteophytes and JSN, respectively, they
hardly contributed to each other in predicting radiographic pro-
gression. For burden this is reasonably explained by the large
predictive ability of baseline radiographic damage, for progression
this remains speculative.
For skin pentosidine the strongest relation with JSN was ex-
pected since pentosidine formation negatively inﬂuences the
biochemical and biomechanical aspect of the cartilage tissue27.
However the strongest relation was observed with osteophyte
formation. Osteophytes probably don’t have a direct role in disease
progression but may serve as markers of the location and severity
of the pathologic process28. Cartilage can have focal damage not
inﬂuencing joint space on radiographs yet. In this early phase
osteophytes may already be formed at the areas with focal damage
and can be seen earlier on radiographs than JSN.
Table III
Multivariable analysis for skin pentosidine and uCTXII as well as the combination, with radiographic progression and burden as dependent variable.
Skin pentosidine uCTXII Combination
B P R2 B P R2 B P R2
K&L progression AUC
Skin pentosidine 1.74 0.01 NA NA
uCTXII NA NA 2.5 <0.001 2.5 <0.010
Age 0.11 0.10
BMI 4.48 0.03
K&L burden AUC
Skin pentosidine 2.5 0.01 NA NA 1.7 0.10
uCTXII NA NA 2.5 <0.001 2.5 <0.001
BMI 4.2 0.05 0.14 0.17 0.17
Baseline rad. 5.4 <0.001 0.69 5.0 <0.001 0.67 5.1 <0.001 0.68
JSN progression AUC
Skin pentosidine 0.6 0.05 NA NA
uCTXII NA NA 0.5 0.02 0.5 0.02
BMI 1.1 0.09
JSN burden AUC
Skin pentosidine NA NA
uCTXII NA NA 0.07 1.7 <0.001 0.10 1.7 0.02 0.10
Baseline rad. 4.9 <0.001 0.87 4.8 <0.001 0.88 4.8 <0.001 0.88
Osteophytes progression AUC
Skin pentosidine 1.1 <0.001 NA NA 1.0 0.02
uCTXII NA NA
BMI 2.3 <0.001 2.4 0.01 1.9 0.02
Baseline rad. 0.6 <0.001 0.6 <0.001 0.6 <0.001
Kidney function 0.01 0.09 0.01 0.10
Osteophytes burden AUC
Skin pentosidine 0.6 0.01 NA NA 0.5 0.01
uCTXII NA NA
BMI 0.9 0.03 0.08 0.12 0.9 0.07 0.11
Baseline rad. 2.1 <0.001 0.85 2.1 <0.001 0.83 2.0 <0.001 0.85
Regression coefﬁcient and P values are given for the variables in each model. The explained variance (R2) for the AUC progression models for all three outcome parameters
(sum K&L, Altman JSN, and Altman osteophytes) is low: between 0.03 and 0.23. For the models AUC burden explained variance (R2) for the whole model (bold) and the whole
model but excluding baseline radiographic data is given, clearly demonstrating the contribution of baseline radiographic damage to themodel. Age, BMI, baseline radiographic
characteristics, kidney function, and gender were added as independent covariables, and removed from the model when not contributing.
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advanced disease. The synovium can be involved in bone matrix
remodeling, synovialmacrophages candifferentiate to form functional
osteoclasts capable of bone remodeling29. Inﬂammatory activity adds
to this process30. AGEs can activate receptor for advanced glycation
endproducts (RAGE) and stimulate chondrocytes and synoviocytes in
the production of pro-inﬂammatory cytokines31. Osteophyte forma-
tion has been related to synovial inﬂammation32. The question is
whether AGEs are responsible for early osteophyte formation through
inﬂammation and so this mechanism can explain the relationship
between skin pentosidine and osteophytes progression and burden.
BMI is associated with OA and AGEs, so BMI was included in the
ﬁnal model. Because not the main focus we did not in further detail
evaluate the association between BMI and AGE. Diabetes is also a
known to be related to AGE formation. In our cohort we have a low
number of participants with reported diabetes. When adding this
into the ﬁnal model no signiﬁcant changes were seen and diabetes
was not related to OA in our study. Because of the uncertainty about
the actual number of diabetes patients (it was not tested for) these
data are not included in the results.
For the radiographic burden baseline radiographic damage
was clearly the best predictive of all variables far out reaching
that of uCTXII or skin pentosidine. When this parameter was
excluded the explained variance of the burden of radiographic
damage with the other independent variables decreased enor-
mously. For both the hip and knee earlier investigations showed
that baseline radiographic parameters are associated with pro-
gression of OA33,34. As such this observation ﬁts very well with
the present knowledge.In conclusion: Skin pentosidine adds to prediction of radio-
graphic progression and burden of osteophyte formation and
uCTXII to radiographic progression and burden of JSN, but overall
skin pentosidine did not perform better than uCTXII in predicting
radiographic damage, and baseline radiographic damage was far
out the best predictor of radiographic burden. Neither of both
biochemical markers is sufﬁciently discriminating to aid to prog-
nosis of radiographic progression in individual patients, nor per-
forms so consistently that it could function as an outcome in clinical
trials.
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